Ther­mo Fish­er grows in­to CGT man­u­fac­tur­ing, while Sam­sung Bi­o­log­ics ex­pands in­to AD­Cs

Ther­mo Fish­er and Sam­sung Bi­o­log­ics, which both have man­u­fac­tur­ing ca­pa­bil­i­ties, ap­pear to have di­ver­gent ap­proach­es to re­cent ser­vice ex­pan­sion plans. Ther­mo is lean­ing in­to new cell and gene ther­a­py work, while Sam­sung is look­ing in­to an­ti­body-drug con­ju­gate ex­pan­sion, ac­cord­ing to their re­spec­tive third-quar­ter earn­ings re­ports.

Ther­mo no­tably de­buted sev­er­al new CGT man­u­fac­tur­ing ser­vices in the past few months. In June, the com­pa­ny in­tro­duced its next-gen­er­a­tion plat­form of cell ther­a­py reagents, dubbed Gib­co CTS De­tach­able Dyn­abeads. It al­so launched its fill-fin­ish ser­vice for bio­phar­ma and CD­MO clients. That said, Ther­mo al­ready has an­ti­body pro­duc­tion ca­pa­bil­i­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER